Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TERN-601 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| TERN-601 | DRUG | Investigational drug |
| Matching Placebo | OTHER | Matching placebo |
TERN-601 is an investigational oral small molecule being developed for the treatment of overweight or obesity. It is a Phase 2 clinical-stage candidate from Terns Pharmaceuticals and has not been approved for any indication. It is being studied in adults with overweight or obesity.
TERN-601 targets the GLP-1 receptor, a receptor that mediates the effects of glucagon-like peptide-1 on appetite and glucose regulation. By acting on this receptor, TERN-601 is designed as an oral small molecule GLP-1 receptor agonist for weight management in overweight or obesity.
TERN-601 is being developed by Terns Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker TERN. The company is the sponsor of the clinical program evaluating the drug in adults with overweight or obesity.
TERN-601 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The completed Phase 2 study enrolled 167 adults with overweight or obesity.
TERN-601 has been evaluated in the Phase 2 trial NCT06854952, titled A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity. That study is listed as completed and enrolled 167 participants with overweight or obesity.